K
The startup develops oral new chemical entities that specifically inhibit TBK1IKKe to treat rare immuno-fibrotic autoimmune diseases such as scleroderma and lupus nephritis. Their approach has demonstrated proof of concept in animal models for improving pulmonary fibrosis and modulating Type I interferon and autoantibodies, enhancing patient quality of life.
Updated 3 months ago
Funding
$29.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops oral new chemical entities that specifically inhibit TBK1IKKe to treat rare immuno-fibrotic autoimmune diseases such as scleroderma and lupus nephritis. Their approach has demonstrated proof of concept in animal models for improving pulmonary fibrosis and modulating Type I interferon and autoantibodies, enhancing patient quality of life.